Cellectis S.A. - American Depositary Shares (CLLS) Covered Calls

You can sell covered calls on Cellectis S.A. - American Depositary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CLLS (prices last updated Wed 4:16 PM ET):

Cellectis S.A. - American Depositary Shares (CLLS) Stock Quote
Last	Change	Bid	Ask	Volume	P/E	Market Cap
1.63	-0.08	1.61	1.71	41K	-	0.0

Covered Calls For Cellectis S.A. - American Depositary Shares (CLLS)
Expiration	Strike	Call Bid	Net Debit	Return If Flat	Annualized Return If Flat
Dec 20	2.5	0.00	1.71	0.0%	0.0%
Jan 17	2.5	0.00	1.71	0.0%	0.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls? Sign Up For A Free Trial

Extended Business Description

Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France

Top 10 Open Interest For Dec 20 Expiration				Top 5 High Yield
1.	NVDA covered calls	6.	EEM covered calls	1.	NVDA covered calls
2.	SPY covered calls	7.	IWM covered calls	2.	RGTI covered calls
3.	XLF covered calls	8.	KWEB covered calls	3.	QUBT covered calls
4.	QQQ covered calls	9.	TLT covered calls	4.	MU covered calls
5.	FXI covered calls	10.	TSLA covered calls	5.	QBTS covered calls

Want more examples? CLIX Covered Calls | CLMT Covered Calls